Skip to main content
رجوع
ABUS logo

Arbutus Biopharma Corporation

جودة البيانات: 100%
ABUS
NASDAQ Healthcare Biotechnology
KWD 4.31
▼ KWD 0.11 (-2.49%)
القيمة السوقية: 829.68M
نطاق اليوم
KWD 4.23 KWD 4.38
نطاق 52 أسبوعًا
KWD 2.71 KWD 5.10
حجم التداول
1,527,873
متوسط 50 يوم / 200 يوم
KWD 4.34 / KWD 4.10
الإغلاق السابق
KWD 4.42

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -24.8 0.4
P/B 10.8 2.9
ROE % -38.5 3.7
Net Margin % -237.9 3.9
Rev Growth 5Y % 6.4 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 8.500 +97.2%
ربحية السهم المستقبلية
-KWD 0.160
الإيرادات المقدّرة
1 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.340
KWD 0.187 – KWD 0.493
170 M 1
FY2028 -KWD 0.140
-KWD 0.203 – -KWD 0.077
56 M 1
FY2027 -KWD 0.050
-KWD 0.073 – -KWD 0.028
8.8 M 1

النقاط الرئيسية

Revenue grew 6.40% annually over 5 years — modest growth
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -39.64M
PEG of 0.50 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 121.81%
Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)
6.40%
Revenue (1Y)128.21%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-38.52%
ROIC-37.01%
Net Margin-237.88%
Op. Margin-270.96%

الأمان

Debt / Equity
0.01
Current Ratio15.73
Interest Coverage393.40

التقييم

P/E Ratio
-24.77
P/B Ratio10.83
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 128.21% Revenue Growth (3Y) -11.89%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 6.40% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14.08M Net Income (TTM) -33.50M
ROE -38.52% ROA -35.41%
Gross Margin 0.00% Operating Margin -270.96%
Net Margin -237.88% Free Cash Flow (TTM) -39.64M
ROIC -37.01% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 15.73
Interest Coverage 393.40 Dividend Yield 0.00%
Valuation
P/E Ratio -24.77 P/B Ratio 10.83
P/S Ratio 58.91 PEG Ratio 0.50
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 829.68M Enterprise Value 812.41M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.08M 6.17M 18.14M 39.02M 10.99M
Net Income -33.50M -69.92M -72.85M -69.46M -76.25M
EPS (Diluted) -0.17 -0.38 -0.44 -0.46 -0.73
Gross Profit 0.0 6.17M 18.14M 39.02M 10.99M
Operating Income -38.16M -76.32M -78.10M -65.46M -73.52M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 94.62M 131.71M 144.40M 195.42M 204.49M
Total Liabilities 18.04M 34.34M 38.38M 58.57M 35.05M
Shareholders' Equity 76.58M 97.37M 106.02M 136.85M 169.44M
Total Debt 746,000.0 1.29M 8.72M 12.55M 18.91M
Cash & Equivalents 18.01M 36.33M 26.29M 30.78M 109.28M
Current Assets 94.46M 127.32M 132.03M 151.14M 160.66M
Current Liabilities 6.01M 15.62M 22.49M 32.86M 11.22M